Cargando…
Antibody and T-Cell Responses to Covid-19 mRNA Vaccines in Patients with B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CLL)
Introduction: While the approval of three commercial vaccines for the SARS-CoV-2 virus has provided upwards of 95% protection against the coronavirus for healthy subjects, the efficacy among patients with hematologic malignancies remains unknown. Immune dysfunction and impaired humoral responses to...
Autores principales: | Ayers, Emily C., Wilson, Jeffrey, Canderan, Glenda, Keshavarz, Behnam, Woodfolk, Judith, Portell, Craig A., Williams, Michael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701483/ http://dx.doi.org/10.1182/blood-2021-146165 |
Ejemplares similares
-
Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy
por: Goel, Shipra, et al.
Publicado: (2021) -
Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies
por: Ollila, Thomas A., et al.
Publicado: (2021) -
In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms
por: Ayers, Emily, et al.
Publicado: (2023) -
Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma
por: Kameda, Takuro, et al.
Publicado: (2023) -
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)